Researchers have uncovered a gene signature that may help predict clinical outcomes in certain types of breast cancer. They report that this gene signature — which is associated with the transforming growth factor-beta (TGF-²) signaling pathway — correlates with reduced relapse-free survival in patients with breast cancer, especially in those with estrogen receptor (ER) positive tumors.